Диссертация (1140369), страница 22
Текст из файла (страница 22)
et al. Evidence of a novel site mediatinganandamide-induced negative inotropic and coronary vasodilatator responses in ratisolated hearts.// J. Pharmacol.-2002. – Vol.135.-P.1191-1198.49. Galbois A, Rudler M, Massard J, Fulla Y, Bennani A, Bonnefont-Rousselot D,et al. Assessment of adrenal function in cirrhotic patients: salivary cortisol should bepreferred. // J Hepatol.
– 2010. – Vol. 52. – №6. – P.839–45.50. Galderisi M., Dini F.L., Temporelli P.L. et al. Doppler echocardiography for theassessment of left ventricular diastolic function: methodology, clinical and prognosticvalue.// Ital. Heart J. Suppl. – 2004. – Vol.5 – P.86-97.51. Garcia-Tsao G, Lim JK; Members of Veterans Affairs Hepatitis C ResourceCenter Program. Management and treatment of patients with cirrhosis and portal142hypertension: recommendations from the Department of Veterans Affairs Hepatitis CResource Center Program and the National Hepatitis C Program.
// Am J Gastroenterol.– 2009. – Vol. 104. – P.1802–1829.52. Garcia-Tsao G, Surawicz CM. Editorial: Clostridium difficile infection: Yetanother predictor of poor outcome in cirrhosis. Am J Gastroenterol. 2010;105:114-116.53. Garcia-Tsao G. Bacterial infections in cirrhosis: treatment and prophylaxis. // J.Hepatol., 2005. - Vol.
42. – P. 85-9254. Gellad Z.F., Alexander B.D., Liu J.K., et al. Severity of Clostridium difficileassociated diarrhea in solid organ transplant patients. Transpl Infect Dis 2007; 9:276280.55. Gines P., Arroyo V., Rodes J., Schrier R.W. Ascites and renal disfunction inliver disease. Blackwell publishing, 2005.56. Gravel D, Miller M, Simor A, et al; Canadian Nosocomial InfectionSurveillance Program. Health care-associated Clostridium difficile infection in adultsadmitted to acute care hospitals in Canada: a Canadian Nosocomial InfectionSurveillance Program Study.
Clin Infect Dis. 2009; 48: 568-576.57. Gunnarsdottir SA, Sadik R, Shev S, Simrén M, Sjövall H, Stotzer PO. Smallintestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosisand portal hypertension. // Am J Gastroenterol. – 2003. – Vol.98. – №6. – P.1362-70.58. Hall, C. Essential biochemistry and physiology of (NT-pro)BNP. // EuropeanJournalofHeartFailure.–2004.–Vol.6.–P.257–260.doi:10.1016/j.ejheart.2003.12.015.59. Hashimoto M, Sugawara Y, Tamura S, Kaneko J, Matsui Y, Togashi J,Makuuch M. Clostridium difficile-associated diarrhea after living donor livertransplantation.
// World J Gastroenterol. – 2007. – Vol.13. – P.2072–2076.60. Henriksen J.N., Getze J.P., Fuglsang S. et al. Increased circulating pro-brainnatriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients withcirrhosis: relationship to cardiovascular dysfunction and severity of disease. // Gut.2003. – 52. – P. 1511-1517.14361. Henriksen J.H., Fuglsang J., Bendtsen F. et al. Dyssynchronous electrical andmechanical systole in patients with cirrhosis.// J. Hepatol. – 2002. – Vol. 36. – P. 513520.62. Huh I.Y., Kim Y.K., Shin W.J., Park S.E., et al. Increased B-type natriureticpeptide during liver transplantation: relationship to invasively measured hemodynamicparameters.
// Transplant Proc. – 2012. – Vol.44. – P.1318-1322.63. Ito Y, Moriwaki H, Muto Y, Kato N, Watanabe K, Ueno K. Effect of lactuloseon short-chain fatty acids and lactate production and on the growth of faecal flora, withspecial reference to Clostridium difficile.
J Med Microbiol 1997; 46: 80-84.64. John S, Thuluvath PJ. Hyponatremia in cirrhosis: pathophysiology andmanagement. // World J Gastroenterol. – 2015. – Vol.21. – №11. – P.3197-205.65. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomaticClostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. Arandomized, placebo-controlled trial. Ann Intern Med 1992; 117:297-302.66. Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives inroom air on moist surfaces and in gastric contents with reduced acidity: a potentialmechanism to explain the association between proton pump inhibitors and C.
difficileassociated diarrhea? Antimicrob Agents Chemother 2007; 51:2883-2887.67. Kalaitzakis E, Bjornsson E. Inadequate use of proton-pump inhibitors in patientswith liver cirrhosis. Eur J Gastroenterol Hepatol 2008; 20: 512 –518.68. Kalaitzakis E, Johansson JE, Bjarnason I, et al. Intestinal permeability incirrhotic patients with and without Ascites // Scand J Gastroenterol. – 2006. – Vol.41. –P.326–330.69. Kelbaek H., Eriksen J., Brynjolf I. et al.
Cardiac performance in patients withasymptomatic alcoholic cirrhosis of the liver. // American J. Cardiology. – 1984. – 54. –P.860-868.70. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT,Edwards E, Therneau TM. Hyponatremia and mortality among patients on the livertransplant waiting list. // N. Engl. J. Med.- 2008.- Sep 4; - Vol. 359(10). – P. 1018-26.14471. Kosar F, Ates F, Sahin I, Karincaoglu M, Yildirim B.
QT interval analysis inpatients with chronic liver disease: a prospective study. // Angiology. – 2007. – Vol.58.– №2. – P. 218-24.72. Kowalski H.J., Abelmann W.H. The cardiac output at rest in Laennec cirrhosis //J Clin Invest. — 1953. — 32:1025–1033.73. La Villa G., Romanelli R.G., Casini Raggi V. et al. Plasma levels of brainnatriuretic peptide in patients with cirrhosis. // Hepatology. – 1992. – 16. – P. 156-161.74. Lakshmi CP, Ghoshal UC, Kumar S, Goel A, Misra A, Mohindra S, et al.Frequency and factors associated with small intestinal bacterial overgrowth in patientswith cirrhosis of the liver and extra hepatic portal venous obstruction.
// Dig Dis Sci. –2010. – Vol.55. – №4. – P.1142-8.75. Lata J., Stiburek O., Kopacova M. Spontaneous bacterial peritonitis: A severecomplication of liver cirrhosis. // World Journal of Gastroenterology. – 2009, Nov. 28.– Vol. 15 (44).
– P. 5505-5510.76. Lee S.S. Cardiac abnormalities in liver cirrhosis.//West J. Med. – 1989.- 151. –P. 530-539.77. Lee S.S., Marty J., Mantz J. et al. Desensitization of myocardial beta-adrenergicreceptors in cirrhotic rats.// Hepatology. – 1990. – Vol. 12. – P. 481-485.78. Lewis SJ, Franco S, Young G, O’Keefe SJ. Altered bowel function andduodenal bacterial overgrowth in patients treated with omeprazole. // AlimentPharmacol Ther. – 1996. – Vol.10. – №4. – P.557–561.79. Licata A, Corrao S, Petta S, Genco C, Cardillo M, et al. NT Pro BNP PlasmaLevel and Atrial Volume Are Linked to the Severity of Liver Cirrhosis. // PLoS ONE. –2013.
– Vol.8. – №8. – e68364. doi:10.1371/journal.pone.0068364.80. Limas C.J., Guiha N.H., Lekagul O. et al. Impaired left ventricular function inalcoholic cirrhosis with ascites: ineffectiveness of ouabain.//Circulation. – 1974. –Vol.49. – P.754-760.81. Lin R.S., Lee F.Y., Lee S.D. et al. Endotoxemia in patients with chronic liverdiseases: relationship to severity of liver diseases, presence of esophageal varices, andhyperdynamic circulation.//J.Hepatol.-1995.-22.-P.165-172.14582.
Lombardo L., Foti M., Ruggia O., Chiecchio A. Increased incidence of smallintestinal bacterial overgrowth during proton pump inhibitor therapy. // Clin.Gastroenterol. Hepatol. – 2010. – Jun; Vol. 8 (6). – P. 504–508.83. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutionaloutbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.N Engl J Med 2005; 353: 2442-2449.84. Ma Z., Lee S.S., Meddings J.B. Effects of altered cardiac membrane fluidity onbeta-adrenergic receptor signaling in rats with cirrhotic cardiomyopathy.//J.Hepatol.
–1997.-26.-P.904-912.85. Ma Z., Lee S.S. Cirrhotic cardiomyopathy: getting to the heart of thematter.//Hepatol.-1996.-24.-P.451-459.86. Ma Z., Miyamoto A., Lee S.S. Role of altered beta-adrenoreceptor signaltransduction in the pathogenesis of cirrhotic cardiomyopathy in rats.//Gastroenterology.1996.-110.-P.1191-1198.87. Maclayton DO, Eaton-Maxwell A. Rifaximin for treatment of hepaticencephalopathy.Ann Pharmacother 2009; 43:77-84.88. Madrid AM, Brahm J, Buckel E, et al. Orthotopic liver transplantation improvessmall bowel motility disorders in cirrhotic patients // Am J Gastroenterol. – 1997. –Vol.92.
– P.1044– 1045.89. Maisel A. B-type natriuretic peptide in the diagnosis and management ofcongestive heart failure. // Cardiol Clin. – 2001. Vol.16. – P.557–71.90. Metwaly A, Khalik AA, Nasr FM, Sabry AI, Gouda MF, Hassan M. BrainNatriuretic Peptide in Liver Cirrhosis and Fatty Liver: Correlation with CardiacPerformance. // Electron Physician. – 2016. – Vol.8. – №2. – P.1984-93. doi:10.19082/1984. eCollection 2016.91.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
